
## Maria Luisa Cañadas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7709391/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The power of genetic diversity in genome-wide association studies of lipids. Nature, 2021, 600, 675-679.	27.8	353
2	PTEN and PI3K/AKT in non-small-cell lung cancer. Pharmacogenomics, 2015, 16, 1843-1862.	1.3	180
3	Apoptosis and necrosis in human ejaculated spermatozoa. Human Reproduction, 2004, 19, 607-610.	0.9	102
4	Genetic Susceptibility to Chronic Kidney Disease – Some More Pieces for the Heritability Puzzle. Frontiers in Genetics, 2019, 10, 453.	2.3	74
5	Genome-wide association meta-analysis for early age-related macular degeneration highlights novel loci and insights for advanced disease. BMC Medical Genomics, 2020, 13, 120.	1.5	56
6	Pharmacogenetic Polymorphisms Contributing to Toxicity Induced by Methotrexate in the Southern Spanish Population with Rheumatoid Arthritis. OMICS A Journal of Integrative Biology, 2012, 16, 589-595.	2.0	46
7	Genetic associations between genes in the renin-angiotensin-aldosterone system and renal disease: a systematic review and meta-analysis. BMJ Open, 2019, 9, e026777.	1.9	42
8	Reduction of False-Negative Papillary Thyroid Carcinomas by the Routine Analysis of BRAFT1799A Mutation on Fine-Needle Aspiration Biopsy Specimens. Annals of Surgery, 2012, 255, 986-992.	4.2	39
9	Proteomic and metabolomic approaches in the search for biomarkers in chronic kidney disease. Journal of Proteomics, 2019, 193, 93-122.	2.4	37
10	Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis. Pharmacological Research, 2016, 111, 264-271.	7.1	35
11	Diabetes-Related Neurological Implications and Pharmacogenomics. Current Pharmaceutical Design, 2018, 24, 1695-1710.	1.9	34
12	Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis. Pharmacogenomics Journal, 2018, 18, 167-172.	2.0	31
13	Genomic approaches in the search for molecular biomarkers in chronic kidney disease. Journal of Translational Medicine, 2018, 16, 292.	4.4	31
14	Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer. Mutation Research - Reviews in Mutation Research, 2017, 771, 32-58.	5.5	30
15	Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients. Pharmacological Research, 2016, 111, 877-884.	7.1	29
16	Liquid biopsy in early stage lung cancer. Translational Lung Cancer Research, 2016, 5, 517-524.	2.8	28
17	Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients. Pharmacogenomics Journal, 2019, 19, 164-177.	2.0	28
18	Effect of <i><scp>CYP</scp>4F2</i> , <i><scp>VKORC</scp>1</i> , and <i><scp>CYP</scp>2C9</i> in Influencing Coumarin Dose: A Singleâ€Patient Data Metaâ€Analysis in More Than 15,000 Individuals. Clinical Pharmacology and Therapeutics, 2019, 105, 1477-1491.	4.7	23

Maria Luisa Cañadas

#	Article	IF	CITATIONS
19	MET: a new promising biomarker in non-small-cell lung carcinoma. Pharmacogenomics, 2015, 16, 631-647.	1.3	21
20	Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer. Breast Cancer Research and Treatment, 2015, 153, 493-505.	2.5	21
21	Pharmacogenetics role in the safety of acenocoumarol therapy. Thrombosis and Haemostasis, 2014, 112, 522-536.	3.4	20
22	Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer. Surgical Oncology, 2017, 26, 278-285.	1.6	20
23	Could 18F-FDG-PET/CT avoid unnecessary thyroidectomies in patients with cytological diagnosis of follicular neoplasm?. Langenbeck's Archives of Surgery, 2013, 398, 709-716.	1.9	19
24	Gene polymorphisms as predictors of response to biological therapies in psoriasis patients. Pharmacological Research, 2016, 113, 71-80.	7.1	19
25	Information on Genetic Variants Does Not Increase Identification of Individuals at Risk of Esophageal Adenocarcinoma Compared to Clinical Risk Factors. Gastroenterology, 2019, 156, 43-45.	1.3	15
26	Molecular biomarkers in colorectal carcinoma. Pharmacogenomics, 2015, 16, 1189-1222.	1.3	14
27	ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: A meta-analysis. Surgical Oncology, 2017, 26, 473-482.	1.6	14
28	The Challenges of Chromosome Y Analysis and the Implications for Chronic Kidney Disease. Frontiers in Genetics, 2019, 10, 781.	2.3	14
29	ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients. Pharmacological Research, 2016, 108, 111-118.	7.1	12
30	Impact of DNA repair, folate and glutathione gene polymorphisms on risk of non small cell lung cancer. Pathology Research and Practice, 2018, 214, 44-52.	2.3	12
31	BRAFT1799A mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma. EndocrinologÃa Y Nutrición (English Edition), 2011, 58, 175-184.	0.5	11
32	Pharmacogenetic biomarkers of response in Crohn's disease. Pharmacogenomics Journal, 2018, 18, 1-13.	2.0	11
33	Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm. Pharmacogenetics and Genomics, 2014, 24, 501-513.	1.5	10
34	Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients. Mutation Research - Reviews in Mutation Research, 2019, 781, 63-70.	5.5	10
35	Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma. Surgical Oncology, 2020, 35, 388-398.	1.6	10
36	Association of ABCB1 and VEGFA gene polymorphisms with breast cancer susceptibility and prognosis. Pathology Research and Practice, 2020, 216, 152860.	2.3	10

Maria Luisa Cañadas

#	Article	IF	CITATIONS
37	Pharmacogenetics of Osteoporosis: Towards Novel Theranostics for Personalized Medicine?. OMICS A Journal of Integrative Biology, 2012, 16, 638-651.	2.0	9
38	Cytokine single-nucleotide polymorphisms and risk of non-small-cell lung cancer. Pharmacogenetics and Genomics, 2017, 27, 438-444.	1.5	9
39	<i>De novo</i> resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer. Pharmacogenomics, 2015, 16, 1411-1426.	1.3	7
40	Extrapolation of acenocoumarol pharmacogenetic algorithms. Vascular Pharmacology, 2015, 74, 151-157.	2.1	5
41	Relevance of <i>BRAF</i> and <i>NRAS</i> mutations in the primary tumor and metastases of papillary thyroid carcinomas. Head and Neck, 2016, 38, 1772-1779.	2.0	5
42	Novel BRAFI599Ins Mutation Identified in a Follicular Variant of Papillary Thyroid Carcinoma: A Molecular Modeling Approach. Endocrine Practice, 2014, 20, e75-e79.	2.1	4
43	MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer. Pharmacological Research, 2015, 102, 90-106.	7.1	4
44	Pharmacogenetic Predictors of Response to Interferon Beta Therapy in Multiple Sclerosis. Molecular Neurobiology, 2021, 58, 4716-4726.	4.0	4
45	Pharmacogenetics and Pharmacogenomics of Chronic Kidney Disease Comorbidities and Kidney Transplantation. , 2013, , 801-817.		2
46	Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRuCIAL study. Blood Cancer Journal, 2022, 12, 79.	6.2	1
47	Pharmacogenetics of Oral Anticoagulants. , 2013, , 435-467.		0
48	Pharmacogenomics and Gut Microbiota Biomarkers in Obesity. , 2013, , 575-601.		0
49	Genetic Strategies to Understand Human Diabetic Nephropathy: In Silico Strategies for Molecular Data—Association Studies. Methods in Molecular Biology, 2020, 2067, 241-275.	0.9	0